Draft genome sequence of Streptomyces rapamycinicus strain NRRL 5491, the producer of the immunosuppressant rapamycin

Genome Announcements

Volumn 1, Issue 4, 2013, Pages

  Baranasic, Damir ^d,e   Gacesa, Ranko ^d   Starcevic, Antonio ^d   Zucko, Jurica ^d   Blažič, Marko ^a   Horvat, Marinka ^a   Gjuračić, Krešimir ^a   Fujs, Štefan ^a   Hranueli, Daslav ^d   Kosec, Gregor ^a,c   Cullum, John ^e   Petković, Hrvoje ^a,b  

^a ACIES BIO D O O   (Slovenia)

^b UNIVERSITY OF CANTABRIA   (Spain)

^c Centre of Excellence for Integrated Approaches in Chemistry and Biology of Proteins CipKeBiP   (Slovenia)

^d UNIVERSITY OF ZAGREB   (Croatia)

^e Rheinland Pfälzische Technische Universität Kaiserslautern Landau   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84997822091     PISSN: None     EISSN: 21698287     Source Type: Journal    
DOI: 10.1128/genomeA.00581-13     Document Type: Article

References (14)

1. Kumar Y, Goodfellow M. 2008. Five new members of the Streptomyces violaceusniger 16S rRNA gene clade: Streptomyces castelarensis sp. nov., comb. nov., Streptomyces himastatinicus sp. nov., Streptomyces mordarskii sp. nov., Streptomyces rapamycinicus sp. nov., and Streptomyces ruanii sp. nov. Int. J. Syst. Evol. Microbiol. 58:1369-1378. doi:10.1099/ijs.0.65408-0.
2. Vézina C, Kudelski A, Sehgal SN. 1975. Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. 28:721-726.
3. Alayev A, Holz MK. 2013. mTOR signaling for biological control and cancer. J. Cell. Physiol. 228:1658-1664.
4. Groth CG, Bäckman L, Morales JM, Calne R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol JM, Durand D, Wramner L, Brattström C, Charpentier B. 1999. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study group. Transplantation 67:1036-1042.
5. Slavin L, Chhabra A, Tobis JM. 2007. Drug-eluting stents: preventing restenosis. Cardiol. Rev. 15:1-12.
6. Laplante M, Sabatini DM. 2012. mTOR signaling in growth control and disease. Cell 149:274-293.
7. Pópulo H, Lopes JM, Soares P. 2012. The mTOR signalling pathway in human cancer. Int. J. Mol. Sci. 13:1886-1918.
8. Ruan B, Pong K, Jow F, Bowlby M, Crozier RA, Liu D, Liang S, Chen Y, Mercado ML, Feng X, Bennett F, von Schack D, McDonald L, Zaleska MM, Wood A, Reinhart PH, Magolda RL, Skotnicki J, Pangalos MN, Koehn FE, Carter GT, Abou-Gharbia M, Graziani EI. 2008. Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proc. Natl. Acad. Sci. U. S. A. 105:33-38.
9. Bové J, Martínez-Vicente M, Vila M. 2011. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat. Rev. Neurosci. 12: 437-452.
10. Johnson SC, Rabinovitch PS, Kaeberlein M. 2013. mTOR is a key modulator of ageing and age-related disease. Nature 493:338-345.
11. Ruan X, Stassi D, Lax SA, Katz L. 1997. A second type-I PKS gene cluster isolated from Streptomyces hygroscopicus ATCC 29253, a rapamycinproducing strain. Gene 203:1-9.
12. Lukashin AV, Borodovsky M. 1998. GeneMark.hmm: new solutions for gene finding. Nucleic Acids Res. 26:1107-1115.
13. Starcevic A, Zucko J, Simunkovic J, Long PF, Cullum J, Hranueli D. 2008. ClustScan: an integrated program package for the semi-automatic annotation of modular biosynthetic gene clusters and in silico prediction of novel chemical structures. Nucleic Acids Res. 36:6882-6892.
14. Medema MH, Blin K, Cimermancic P, de Jager V, Zakrzewski P, Fischbach MA, Weber T, Breitling R, Takano E. 2011. antiSMASH: rapid identification, annotation and analysis of secondary metabolite biosynthesis gene clusters. Nucleic Acids Res. 39:W339-W346. doi:10.1093/nar/gkr466.